The correct action is to
pause the analgesia pump, notify the physician, and observe closely. The patient’s respiratory rate of
12/min and oxygen saturation of
96% may appear acceptable, but they are not reassuring in this context because sedation precedes respiratory depression in opioid toxicity.
Understanding the Pasero Opioid-Induced Sedation Scale
The patient’s presentation — frequently drowsy and drifting off in the middle of answering questions — corresponds to
level 3 on the Pasero Opioid-Induced Sedation Scale (POSS). This scale is the standard tool recommended by the American Society for Pain Management Nursing (ASPMN) for monitoring hospitalized adults receiving opioid analgesics
[1][2]. The levels are defined by observable behavior:
| POSS Level | Behavior | Nursing Action |
|---|
| S = Sleep | Easy to arouse, normal sleep | No action; continue monitoring |
| 1 | Awake and alert | No action; continue monitoring |
| 2 | Occasionally drowsy, easy to arouse, drifts off during conversation | Reduce opioid dose; increase monitoring frequency |
| 3 | Frequently drowsy, drifts off mid-sentence, arouses with difficulty | Hold opioid, notify prescriber, observe closely |
| 4 | Somnolent, minimal or no response to physical stimulation | Stop opioid, administer naloxone, call rapid response |
The patient’s behavior of drifting off
in the middle of answering questions is the key discriminator between level 2 and level 3. Level 2 involves occasional drowsiness with easy arousal, whereas level 3 involves frequent drowsiness and difficulty staying awake during conversation. The correct response at level 3 is to
hold or reduce the opioid,
notify the prescriber, and
monitor closely [1][2][3].
Why Normal Oxygen Saturation Does Not Mean the Patient Is Safe
A central teaching point in opioid safety monitoring is that
sedation always precedes opioid-induced respiratory depression. The patient becomes progressively sedated before the respiratory rate falls and before oxygen desaturation occurs
[1][4]. This sequence is critical because it means that by the time oxygen saturation drops, the patient is already in a late stage of respiratory compromise.
Supplemental oxygen at
2 L/min via nasal cannula can mask hypoventilation by maintaining a normal or near-normal SpO₂ even when the patient is retaining carbon dioxide and breathing inadequately
[1][4]. In other words,
a normal oxygen saturation on supplemental oxygen does not rule out clinically significant respiratory depression. The respiratory rate of
12/min is at the lower end of normal, but in a patient who is also sedated, it should raise concern rather than provide reassurance.
Why the Other Options Are Incorrect
Option 1 — letting her rest because the numbers are normal — is dangerous because it ignores the sedation level, which is the earliest and most reliable indicator of impending respiratory depression
[1][2]. The ASPMN guidelines explicitly state that sedation assessment must be integrated into every opioid administration decision, not just vital sign monitoring
[4].
Option 3 — administering naloxone
0.4 mg IV push to fully reverse the opioid — is premature and potentially harmful. Naloxone is indicated for POSS level 4 or actual respiratory arrest, not for level 3 sedation
[1][2]. Full reversal can precipitate severe pain, sympathetic surge, pulmonary edema, and cardiac arrhythmias. The goal at level 3 is to hold the opioid and observe, not to reverse it completely.
Option 4 — raising oxygen to
4 L/min and rechecking in 1 hour — is unsafe for two reasons. First, increasing oxygen does not address the underlying opioid-induced sedation. Second, waiting 1 hour to reassess a patient at POSS level 3 is far too long; these patients require frequent, often continuous, monitoring
[1][3].
Watch out! A common exam trap is to focus on the respiratory rate and oxygen saturation while ignoring the sedation level. The sedation score is the primary assessment parameter for opioid safety.
Key point! At POSS level 3, the nurse holds the opioid, notifies the prescriber, and observes closely. Naloxone is reserved for level 4 or respiratory arrest.
References (research sources)
- [1]
American Society for Pain Management Nursing Guidelines on Monitoring for Opioid-Induced Advancing Sedation and Respiratory Depression: Revisions.GuidelineJungquist CR, Quinlan-Colwell A, Vallerand A, Carlisle HL, Cooney M, Dempsey SJ (2020) · DOI: 10.1016/j.pmn.2019.06.007
- [2]
American Society for Pain Management Nursing guidelines on monitoring for opioid-induced sedation and respiratory depression.GuidelineJarzyna D, Jungquist CR, Pasero C, Willens JS, Nisbet A, Oakes L (2011) · DOI: 10.1016/j.pmn.2011.06.008
- [3]
Implementing a Clinical Practice Guideline on Opioid-Induced Advancing Sedation and Respiratory Depression.GuidelineKamendat J, Dabney BW, McFarland M, Gilbert GE, Richards-Weatherby K (2020) · DOI: 10.1097/NCQ.0000000000000406
- [4]
Opioid-Induced Sedation and Respiratory Depression: Are Sedation Scales Enough to Prevent Adverse Drug Events Postoperatively?Research articleDunwoody DR, Jungquist CR (2020) · DOI: 10.1016/j.pmn.2018.09.009